Michael Halpin Sells Shares of VCEL $VCEL
Key Points
- Michael Halpin sold 10,000 shares of Vericel Corporation ($VCEL) worth $402,400.
- $VCEL last traded around $40.47.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Michael Halpin, Chief Operating Officer at Vericel Corporation ($VCEL), sold 10,000 shares at an average price of $40.24, for a total transaction of $402,400. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vericel Corporation Stock Down 1.2%
Shares of Vericel Corporation ($VCEL) traded around $40.47 on Tuesday, down 1.2% for the day.
Vericel Corporation Earnings
Analysts Set New Price Targets
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Get Vericel Corporation alerts
New 13F filings, insider trades, and analyst moves on $VCEL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.